Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Olema Pharmaceuticals (NASDAQ:OLMA) and maintained a $21 price target.
March 12, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating and a $21 price target on Olema Pharmaceuticals.
The reiteration of an Outperform rating and the maintenance of a $21 price target by a reputable analyst like Matthew Biegler from Oppenheimer could instill confidence among investors and potentially lead to a positive short-term price movement for Olema Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100